Tradestie Institutional Equity Comparison Engine
VIVS vs SRZN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRZN Overall Edge
SRZN Captures Institutional Edge (3โ0 Pillars ยท 7โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VIVS trades at N/M Forward P/E with -10117.0% operating margin (-51.4% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
VIVS N/M vs SRZN N/M Fwd P/E
Growth & Margin Winner
SRZN
Op Margin -10117.0% vs -485.4% ยท YoY -51.4% vs +408.6%
Momentum & Technical Winner
SRZN
1Y -87.0% vs +136.8% ยท 52W Pos 5% vs 72%
Options & Structure Winner
SRZN
BREAKDOWN (N/A IV) vs CONSOLIDATION (5th %ile IV)
VIVS
NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap
$2.4M
1M Return
+64.69%
1Y Return
-86.99%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 5.0
Fund 38.0
Flow 50.0
Mom 50.0
SRZN
NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$30.67
-3.37% 1D
Market Cap
$665.1M
1M Return
+21.13%
1Y Return
+136.83%
Forward P/E
N/M
Unified AI Score
42.8 / 100
HOLD
Tech 15.0
Fund 48.0
Flow 64.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
VIVS -86.99%
SRZN +136.83%
Spread: +223.82 pp (SRZN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VIVS Revenue | SRZN Revenue | VIVS Op. Margin | SRZN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -766.3% | N/A | VIVS |
| FY2019 | $0M | N/A | -882.4% | N/A | VIVS |
| FY2020 | $0M | N/A | -977.9% | N/A | VIVS |
| FY2022 | $0M | $10M | -765.3% | -354.7% | SRZN |
| FY2023 | $0M | N/A | -4792.2% | N/A | VIVS |
| FY2024 | $0M | $10M | -13840.4% | -239.7% | SRZN |
| FY2025 | $0M | $0M | -8761.1% | -1210.6% | SRZN |
| FY2026 | $0M | N/A | -8768.7% | N/A | VIVS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VIVS | SRZN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.4M | $665.1M | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -51.4% | +408.6% | Higher Growth | SRZN |
| Operating Margin (TTM) Profitability | -10117.0% | -485.4% | Higher Margin | SRZN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -343.1% | -62.8% | Higher ROE | SRZN |
| 52-Week Range Position Momentum | 5% ($0โ$3) | 72% ($13โ$38) | Stronger Trend | SRZN |
| Beta / 30D Volatility Risk Regime | 0.83ฮฒ ยท 480% Vol | 1.25ฮฒ ยท 70% Vol | Lower Realized Risk | SRZN |
| Unified Institutional Score Composite Signal | 36.8 / 100 (SELL) | 42.8 / 100 (HOLD) | Higher Composite | SRZN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full VIVS vs SRZN Buy Guide
VIVS
BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
SRZN
CONSOLIDATION
40d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither VIVS nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.